Recombinant Human CACNa1D protein

中文名： L-型电压依赖性钙离子通道α1D亚基(CACNa1D)重组蛋白
别名： CACNa1D；CACH3；CACN4；CACNL1A2；Voltage-dependent L-type calcium channel subunit alpha-1D

货号: PA2000-296DB

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	CACNa1D
Uniprot No	Q01668
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	全长
氨基酸序列	full
预测分子量	kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于CACNA1D重组蛋白的3篇代表性文献及其摘要概括：

---

1. **文献名称**：*"Recombinant expression and functional characterization of Cav1.3 voltage-gated calcium channels"*

**作者**：Lieb A. et al.

**摘要**：该研究通过HEK293细胞成功重组表达了人源CACNA1D编码的Cav1.3钙通道，并利用膜片钳技术分析了其电生理特性。研究发现，重组蛋白表现出典型的L型钙通道激活和失活特性，并验证了其对二氢吡啶类药物的敏感性，为后续药物筛选提供了模型。

2. **文献名称**：*"Structural insights into the human Cav1.3 channel by cryo-EM"*

**作者**：Zhong X. et al.

**摘要**：本研究通过冷冻电镜技术解析了重组表达的人Cav1.3通道蛋白(CACNA1D)的高分辨率三维结构，揭示了其α1亚基与辅助亚基(β和α2δ)的相互作用位点，为理解疾病相关突变及药物开发提供了结构基础。

3. **文献名称**：*"Pathogenic CACNA1D mutations enhance voltage-sensitive inactivation in recombinant human Cav1.3 channels"*

**作者**：Scholl U.I. et al.

**摘要**：该研究在HEK细胞中表达了携带原发性醛固酮增多症相关突变的CACNA1D重组蛋白，发现突变导致Cav1.3通道的电压依赖性失活增强，进而引起肾上腺细胞钙信号异常，阐明了突变致病的分子机制。

---

**说明**：以上文献为示例性质，实际研究中建议通过PubMed或Google Scholar以关键词“CACNA1D recombinant”或“Cav1.3 expression”检索最新文献。关注领域内权威期刊如*Nature Structural & Molecular Biology*、*Journal of Biological Chemistry*等可获取更精准信息。

背景信息

**Background of CACNA1D Recombinant Protein**

The CACNA1D gene encodes the α1D subunit of voltage-gated L-type calcium channels (LTCCs), specifically forming the Cav1.3 channel. These channels are critical for converting electrical signals into cellular responses, such as muscle contraction, hormone secretion, and neuronal excitability. CACNA1D is predominantly expressed in the brain, pancreatic β-cells, heart, and adrenal glands, where it regulates calcium influx in response to membrane depolarization.

CACNA1D recombinant proteins are engineered in vitro to study the structure, function, and pharmacological properties of Cav1.3 channels. These proteins are typically expressed in heterologous systems (e.g., mammalian cells, insect cells) to ensure proper post-translational modifications and channel activity. Researchers utilize recombinant CACNA1D to investigate its role in physiological processes, including cardiac pacemaking, neurotransmitter release, and insulin secretion.

Dysregulation of CACNA1D is linked to human diseases. Gain-of-function mutations are associated with primary aldosteronism, a cause of severe hypertension, while loss-of-function variants may contribute to congenital sinus node dysfunction. CACNA1D has also been implicated in neurodevelopmental disorders, such as autism spectrum disorders, and is explored as a therapeutic target for cardiovascular and neurological conditions.

Recombinant CACNA1D enables high-throughput drug screening and mechanistic studies, particularly for LTCC blockers (e.g., dihydropyridines) and activators. Its structural analysis via cryo-EM or X-ray crystallography provides insights into channel gating and ligand interactions. Overall, CACNA1D recombinant proteins serve as essential tools for advancing basic research and developing precision therapies targeting calcium channelopathies.